国家医保局联合国家卫生健康委正式公布了《国家基本医疗保险、生育保险和工伤保险药品目录(2026年)》及《商业健康保险创新药品目录(2026年)》,两项新目录均定于2027年1月1日起执行 1。此次基本医保目录调整新增107种药品,其中包含51种1类创新药;备受关注的CAR-T药物瑞基奥仑赛注射液首次被纳入基本医保目录,该药物此前定价为每支129万元 1。与此同时,商保创新药目录新增了12种药品,调整后总数达到28种 1。
为了实现多层次保障体系的协同,此次调整建立了基本医保与商业健康保险创新药的衔接机制,盐酸沙丙蝶呤片与瑞基奥仑赛注射液从商保目录转入基本医保目录 1。在扩容的同时,有34种药品被调出目录,其中4种协议期内的谈判药品设置了过渡期安排,允许其使用至2027年6月底,以保障患者用药的连续性 1。回顾历史数据,2018年至2024年间共有530种药品通过医保谈判进入目录,仅2025年的相关采购金额就达到了1725亿元 1。
为确保新目录顺利落地,省级医保部门需在2026年12月底前完成新增药品的挂网工作 1。此外,定点医疗机构原则上应于2027年2月底前召开药事委员会会议,及时调整并配备相关药品 1。
China’s National Healthcare Security Administration and the National Health Commission have released the updated "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2026)" alongside the "Commercial Health Insurance Innovative Drug Catalog (2026)," both of which are scheduled to take effect on January 1, 2027 1. This adjustment establishes a new mechanism linking basic medical insurance with commercial health insurance innovative drugs, aiming to expand multi-channel payment pathways while ensuring continuity of care for patients 1. The basic medical insurance catalog has added 107 new drugs, including 51 Class I innovative medications, while the commercial health insurance innovative drug catalog expanded by 12 drugs, bringing its total count to 28 after adjustments 1.
A significant highlight of the update is the inclusion of the CAR-T therapy drug Relmacabtagene autoleucel in the basic medical insurance catalog for the first time; this treatment was previously priced at 1.29 million yuan per injection 1. Additionally, Sapropterin hydrochloride tablets and Relmacabtagene autoleucel were transferred from the commercial health insurance catalog into the basic medical insurance list 1. To facilitate this transition, provincial healthcare security departments must complete the online listing of new drugs by the end of December 2026, and designated medical institutions are required to adjust their drug inventories through pharmaceutical committees by the end of February 2027 1.
In terms of removals, 34 drugs were excluded from the catalogs, with four negotiated drugs within their agreement period granted a transition period lasting until the end of June 2027 1. These changes build upon previous efforts; from 2018 to 2024, a total of 530 drugs entered the national catalog through medical insurance negotiations, with procurement amount reaching 172.5 billion yuan in 2025 1.
评论
还没有评论,欢迎留下第一条。